Interpace Biosciences Inc
interpace.comInterpace Biosciences (NASDAQ: IDXG) is a molecular diagnostics company that develops and sells proprietary genomic tests for cancer risk assessment in indeterminate thyroid nodules. Revenue is transactional, generated when physicians order tests and the company bills Medicare, Medicare Advantage, Medicaid, commercial payers such as Blue Cross Blue Shield, Aetna, Cigna, and United Healthcare, and direct clients such as hospitals and clinics. The company's primary products are ThyGeNEXT, a next-generation DNA and RNA sequencing oncogene and mRNA fusion panel, and ThyraMIR v2, a microRNA-based endocrine cancer diagnostic assay. These two tests are sold as a combined platform. Testing is performed in a single CLIA-certified and CAP-accredited laboratory in Pittsburgh, Pennsylvania. The largest customer in FY2025 was Laboratory Corporation of America. The company estimated the total addressable market for its endocrine cancer assays at approximately $300 million annually. As of FY2025, the company generated positive operating cash flows and carried a term loan with $4.4 million in principal repayments made during the year. Thomas W. Burnell serves as President and CEO.
Products & Services
ThyGeNEXT: next-generation DNA and RNA sequencing oncogene and mRNA fusion panel evaluating mutations associated with thyroid cancer, including RET and NTRK markers. ThyraMIR v2: microRNA-based endocrine cancer diagnostic assay measuring expression of eleven distinct microRNAs. Both are sold as a combined testing platform for risk stratification of indeterminate thyroid nodules (10-K filed 2026-03-30).
Revenue Model
Transactional fee-for-service: the company bills payers and direct clients each time a molecular diagnostic test is ordered. Payer mix includes Medicare, Medicare Advantage, Medicaid, and commercial insurers, plus direct billing to hospitals and clinics (FY2025, 10-K filed 2026-03-30).
Customers & Markets
Customers are physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. Largest single customer in FY2025 was Laboratory Corporation of America (LabCorp). End market is endocrine and thyroid cancer diagnosis. Payer channels include Medicare, Medicare Advantage, Medicaid, Blue Cross Blue Shield, Aetna, Cigna, and United Healthcare (10-K filed 2026-03-30).
Geographic Exposure
Operations conducted from a single laboratory in Pittsburgh, Pennsylvania. No international operations referenced in the filing excerpts (10-K filed 2026-03-30).
Loading...
